Woodline Partners’s Vor Biopharma VOR Stock Holding History

Woodline Partners’s Portfolio VOR Stock Details VOR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$6.99M	Buy	+379,723	New	+$5.75M	0.02%	609
2025 Q4	–	Sell	-27,363	Closed	-$1.33M	–	1123
2025 Q3	$1.33M	Buy	+27,363	New	+$1.1M	0.01%	778
2024 Q2	–	Sell	-55,556	Closed	-$2.63M	–	680
2024 Q1	$2.63M	Hold	55,556	–	–	0.02%	412
2023 Q4	$2.5M	Hold	55,556	–	–	0.03%	367
2023 Q3	$2.36M	Hold	55,556	–	–	0.03%	384
2023 Q2	$3.43M	Hold	55,556	–	–	0.04%	350
2023 Q1	$5.98M	Hold	55,556	–	–	0.08%	265
2022 Q4	$7.39M	Hold	55,556	–	–	0.1%	259
2022 Q3	$4.42M	Hold	55,556	–	–	0.06%	321
2022 Q2	$5.52M	Hold	55,556	–	–	0.09%	246
2022 Q1	$6.71M	Hold	55,556	–	–	0.11%	216
2021 Q4	$12.9M	Hold	55,556	–	–	0.18%	154
2021 Q3	$17.4M	Sell	55,556 -1,769	-3%	-$526K	0.28%	100
2021 Q2	$21.4M	Sell	57,325 -338	-0.6%	-$167K	0.4%	64
2021 Q1	$49.7M	Buy	+57,663	New	+$48.8M	1.1%	14

Other funds holding VOR

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

FIS

FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return

Woodline Partners's VOR Position: Q2 2026 in Review

Woodline Partners opened a new position in Vor Biopharma (VOR) in Q2 2026: 379,723 shares worth $6.99M. The stake represents 0.02% of the portfolio and ranks #609 among its holdings. This is a return to the name: Woodline Partners previously reported a position in VOR as recently as Q3 2025.

Woodline Partners first reported a position in VOR in Q1 2021 and has held it in 15 quarters since. The position peaked at $49.7M in Q1 2021. 102 funds tracked by Wall St. Rank hold VOR as of Q2 2026.

Woodline Partners held 379,723 shares of Vor Biopharma worth $6.99M as of Q2 2026.
Vor Biopharma was a new Woodline Partners position in Q2 2026.
Vor Biopharma made up 0.02% of Woodline Partners's portfolio in Q2 2026, its #609 holding.
Woodline Partners first reported a position in Vor Biopharma in Q1 2021 and has held it in 15 quarters since.
Woodline Partners's Vor Biopharma position peaked at $49.7M in Q1 2021.
102 funds tracked by Wall St. Rank held Vor Biopharma as of Q2 2026.

Based on Woodline Partners's 13F filing for Q2 2026, filed 14 Aug 2026.